Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease

Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer’s disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temp...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Rep
Main Authors: Cavedo, Enrica, Grothe, Michel J., Colliot, Olivier, Lista, Simone, Chupin, Marie, Dormont, Didier, Houot, Marion, Lehéricy, Stephane, Teipel, Stefan, Dubois, Bruno, Hampel, Harald
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601919/
https://ncbi.nlm.nih.gov/pubmed/28916821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-09780-3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki